SK280299B6 - Transdermálny terapeutický systém a spôsob jeho vý - Google Patents
Transdermálny terapeutický systém a spôsob jeho vý Download PDFInfo
- Publication number
- SK280299B6 SK280299B6 SK219-97A SK21997A SK280299B6 SK 280299 B6 SK280299 B6 SK 280299B6 SK 21997 A SK21997 A SK 21997A SK 280299 B6 SK280299 B6 SK 280299B6
- Authority
- SK
- Slovakia
- Prior art keywords
- transdermal therapeutic
- therapeutic system
- water
- estradiol
- binding
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 34
- 229960005309 estradiol Drugs 0.000 claims abstract description 34
- 229930182833 estradiol Natural products 0.000 claims abstract description 32
- 239000011159 matrix material Substances 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000000654 additive Substances 0.000 claims description 15
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 11
- 239000011707 mineral Substances 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- -1 alkali metal salt Chemical class 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000011888 foil Substances 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 239000002274 desiccant Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 8
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 12
- 235000010755 mineral Nutrition 0.000 description 7
- 235000011132 calcium sulphate Nutrition 0.000 description 6
- 230000007423 decrease Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 239000000395 magnesium oxide Substances 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 3
- 229920006267 polyester film Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 150000004645 aluminates Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001175 calcium sulphate Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920004939 Cariflex™ Polymers 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- MPCRDALPQLDDFX-UHFFFAOYSA-L Magnesium perchlorate Chemical compound [Mg+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O MPCRDALPQLDDFX-UHFFFAOYSA-L 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AMWRITDGCCNYAT-UHFFFAOYSA-L manganese oxide Inorganic materials [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 1
- PPNAOCWZXJOHFK-UHFFFAOYSA-N manganese(2+);oxygen(2-) Chemical class [O-2].[Mn+2] PPNAOCWZXJOHFK-UHFFFAOYSA-N 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Auxiliary Drives, Propulsion Controls, And Safety Devices (AREA)
- Traffic Control Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4429664A DE4429664C2 (de) | 1994-08-20 | 1994-08-20 | Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung |
| PCT/EP1995/003202 WO1996005815A1 (fr) | 1994-08-20 | 1995-08-12 | Systeme therapeutique transdermique contenant de l'×stradiol et des additifs hydrophiles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK21997A3 SK21997A3 (en) | 1997-07-09 |
| SK280299B6 true SK280299B6 (sk) | 1999-11-08 |
Family
ID=6526229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK219-97A SK280299B6 (sk) | 1994-08-20 | 1995-08-12 | Transdermálny terapeutický systém a spôsob jeho vý |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0776197B1 (fr) |
| JP (1) | JPH10504314A (fr) |
| KR (1) | KR100374476B1 (fr) |
| CN (1) | CN1073413C (fr) |
| AT (1) | ATE173163T1 (fr) |
| AU (1) | AU700119B2 (fr) |
| CA (1) | CA2197865C (fr) |
| CZ (1) | CZ50897A3 (fr) |
| DE (2) | DE4429664C2 (fr) |
| DK (1) | DK0776197T3 (fr) |
| ES (1) | ES2126308T3 (fr) |
| FI (1) | FI118721B (fr) |
| HU (1) | HUT77093A (fr) |
| IL (1) | IL114948A (fr) |
| NO (1) | NO970553D0 (fr) |
| NZ (1) | NZ291449A (fr) |
| PL (1) | PL180943B1 (fr) |
| SI (1) | SI0776197T1 (fr) |
| SK (1) | SK280299B6 (fr) |
| WO (1) | WO1996005815A1 (fr) |
| ZA (1) | ZA956926B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6623763B2 (en) | 1996-01-08 | 2003-09-23 | Lts Lohmann Therape-System Ag | Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism |
| DE19600347A1 (de) * | 1996-01-08 | 1997-07-10 | Lohmann Therapie Syst Lts | Hauthaftende pharmazeutische Zubereitung, insbesondere TTS zur Abgabe von 17-beta-Estradiol an den menschlichen Organismus |
| GB9720470D0 (en) | 1997-09-25 | 1997-11-26 | Ethical Pharmaceuticals South | Inhibition of crystallization in transdermal devices |
| DE19827732A1 (de) * | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991005529A1 (fr) * | 1989-10-13 | 1991-05-02 | Watson Laboratories, Inc. | Systemes d'apport de medicaments et matrice prevue a cet effet |
| DE4223360C1 (fr) * | 1992-07-16 | 1993-04-08 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| DE4237453C1 (fr) * | 1992-11-06 | 1993-08-19 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| DE4309830C1 (de) * | 1993-03-26 | 1994-05-05 | Lohmann Therapie Syst Lts | Wirkstoffpflaster für die Abgabe von Estradiol an die Haut |
-
1994
- 1994-08-20 DE DE4429664A patent/DE4429664C2/de not_active Expired - Fee Related
-
1995
- 1995-08-12 DE DE59504233T patent/DE59504233D1/de not_active Expired - Lifetime
- 1995-08-12 AU AU32583/95A patent/AU700119B2/en not_active Ceased
- 1995-08-12 AT AT95929104T patent/ATE173163T1/de active
- 1995-08-12 SI SI9530203T patent/SI0776197T1/xx unknown
- 1995-08-12 JP JP8507755A patent/JPH10504314A/ja active Pending
- 1995-08-12 HU HU9701725A patent/HUT77093A/hu unknown
- 1995-08-12 WO PCT/EP1995/003202 patent/WO1996005815A1/fr not_active Ceased
- 1995-08-12 CN CN95194678A patent/CN1073413C/zh not_active Expired - Fee Related
- 1995-08-12 ES ES95929104T patent/ES2126308T3/es not_active Expired - Lifetime
- 1995-08-12 EP EP95929104A patent/EP0776197B1/fr not_active Expired - Lifetime
- 1995-08-12 DK DK95929104T patent/DK0776197T3/da active
- 1995-08-12 NZ NZ291449A patent/NZ291449A/en unknown
- 1995-08-12 KR KR1019970701107A patent/KR100374476B1/ko not_active Expired - Fee Related
- 1995-08-12 SK SK219-97A patent/SK280299B6/sk unknown
- 1995-08-12 CA CA002197865A patent/CA2197865C/fr not_active Expired - Fee Related
- 1995-08-12 CZ CZ97508A patent/CZ50897A3/cs unknown
- 1995-08-15 IL IL11494895A patent/IL114948A/xx not_active IP Right Cessation
- 1995-08-18 ZA ZA956926A patent/ZA956926B/xx unknown
-
1997
- 1997-02-06 NO NO970553A patent/NO970553D0/no not_active Application Discontinuation
- 1997-02-18 PL PL95319014A patent/PL180943B1/pl unknown
- 1997-02-19 FI FI970702A patent/FI118721B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3258395A (en) | 1996-03-14 |
| IL114948A (en) | 2000-10-31 |
| ES2126308T3 (es) | 1999-03-16 |
| SK21997A3 (en) | 1997-07-09 |
| NO970553L (no) | 1997-02-06 |
| IL114948A0 (en) | 1995-12-08 |
| ATE173163T1 (de) | 1998-11-15 |
| ZA956926B (en) | 1996-03-25 |
| DE59504233D1 (de) | 1998-12-17 |
| CZ50897A3 (en) | 1997-06-11 |
| MX9701301A (es) | 1998-05-31 |
| JPH10504314A (ja) | 1998-04-28 |
| PL180943B1 (pl) | 2001-05-31 |
| EP0776197A1 (fr) | 1997-06-04 |
| WO1996005815A1 (fr) | 1996-02-29 |
| AU700119B2 (en) | 1998-12-24 |
| NZ291449A (en) | 1998-09-24 |
| CN1155836A (zh) | 1997-07-30 |
| NO970553D0 (no) | 1997-02-06 |
| KR100374476B1 (ko) | 2003-04-23 |
| CN1073413C (zh) | 2001-10-24 |
| CA2197865A1 (fr) | 1996-02-29 |
| CA2197865C (fr) | 2005-10-25 |
| DE4429664C2 (de) | 1997-09-11 |
| FI118721B (fi) | 2008-02-29 |
| EP0776197B1 (fr) | 1998-11-11 |
| KR970705380A (ko) | 1997-10-09 |
| HUT77093A (hu) | 1998-03-02 |
| SI0776197T1 (en) | 1999-04-30 |
| FI970702L (fi) | 1997-02-19 |
| DK0776197T3 (da) | 1999-07-26 |
| PL319014A1 (en) | 1997-07-21 |
| DE4429664A1 (de) | 1996-02-22 |
| FI970702A0 (fi) | 1997-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5928666A (en) | Crystalline form of estradiol and pharmaceutical formulations comprising same | |
| CA2326662C (fr) | Systeme therapeutique pouvant etre active par l'humidite | |
| CA2372710C (fr) | Stratifies contenant un principe actif pour systemes transdermiques | |
| SK279112B6 (sk) | Spôsob výroby transdermálneho terapeutického systé | |
| EP1089722A1 (fr) | Timbre transdermique, du type matrice, destine a des hormones steroides | |
| SI9300581A (en) | Transdermal therapeutic system with estradiol as activ substance | |
| IL106315A (en) | Transdermal therapeutic system containing 17-beta-estradiol and process for its preparation | |
| SK280299B6 (sk) | Transdermálny terapeutický systém a spôsob jeho vý | |
| SK281626B6 (sk) | Transdermálny terapeutický systém s obsahom estradiolu | |
| CN112826809A (zh) | 一种稳定的妥洛特罗经皮吸收制剂 | |
| MXPA97001301A (en) | Transdermal therapeutic system containing estradiol comprising additives higrofili | |
| JP3002492B2 (ja) | 経皮吸収製剤 | |
| MXPA00009579A (en) | Therapeutic system which can be moisture-activated | |
| JPH07247221A (ja) | 貼付剤 |